| NCT06157151 | PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer | RECRUITING | PHASE2 | 2025-03-21 | 2028-01-30 | 2028-01-30 |
| NCT06538480 | Confirmatory Study of PRGN-2012 in Patients With RRP | SUSPENDED | PHASE3 | 2024-07-11 | 2029-03-01 | 2027-03-01 |
| NCT04724980 | Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2021-03-16 | 2026-06-05 | 2024-06-05 |
| NCT03927261 | PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS | ACTIVE_NOT_RECRUITING | PHASE1 | 2019-05-20 | 2025-08-01 | 2024-08-01 |
| NCT03907527 | Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer | ACTIVE_NOT_RECRUITING | PHASE1 | 2019-04-30 | 2028-11-15 | 2024-12-15 |